Alternate Name(s):
BREVIBLOC®
Classification:
Beta adrenergic blocking agent
Original Date:
August 2005
Revised Date:
September 2011
Indications:
- Perioperative management of hypertension
- Supraventricular tachycardia (control ventricular rate in patients with sinus tachycardia)
Reconstitution and Stability:
- Clear, colorless to light yellow solution
- Store at room temperature
-
Diluted solutions stable 7 days at room temperature or refrigerated
Compatibility:
- Solutions Compatible: D5W, NS, dextrose-saline combinations, ringer's lactate
- Additives/Above Cassette Compatible: no information
- Y-site Compatible: ampicillin, clindamycin, dopamine, enalaprilat, fentanyl, metronidazole, morphine, potassium chloride
- Incompatible: amphotericin B, furosemide, warfarin
Administration:
(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)
| SC | NO |
| IM | NO |
| IV Direct |
YES |
| IV Intermittent Infusion | NO |
| IV Continuous Infusion | YES Usual dilution: 10 mg/mL |
Click here to access SDC Drug Infusion Sheet
Dosage:
(For neonatal dosages, refer to Neonatal IV Drug Manual.)
Pediatric:
- Bolus/Loading dose: 100-500 mcg/kg over 1 minute, followed by an infusion; infusion rate = 100-500 mcg/kg/minute. Maximum 1000 mcg/kg/minute
Potential hazards of parenteral administration:
- Phlebitis, skin necrosis after extravasation
- Hypotension, bradycardia
- Dizziness, flushing, diaphoresis, nausea
- Bronchoconstriction
Notes:
- Onset of action (2-10 minutes)
- Short duration of action (10-30 minutes)
- Monitor blood pressure, EKG, heart rate, respiratory rate and IV site
- Use with caution in patient with hyper-reactive airway disease
- May increase digoxin or theophylline serum concentrations
- Morphine may increase esmolol blood concentrations